^
Phase 3
AstraZeneca
Recruiting
Last update posted :
09/23/2021
Initiation :
12/06/2018
Primary completion :
04/30/2024
Completion :
04/30/2024
EGFR
|
cisplatin • carboplatin • paclitaxel • Imfinzi (durvalumab) • gemcitabine • pemetrexed
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/23/2021
Initiation :
09/20/2021
Primary completion :
03/01/2026
Completion :
03/01/2026
BRCA2 • BRCA1 • HRD • CDK12 • RAD51B • BRIP1 • CHEK2 • RAD51C • RAD51D • CHEK1 • RAD54L • BARD1 • BRCA • FANCL • PPP2R2A
|
BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation • CHEK1 mutation • CHEK1 expression
|
Trodelvy (sacituzumab govitecan-hziy) • berzosertib (M6620)
Phase 3
AstraZeneca
Recruiting
Last update posted :
09/23/2021
Initiation :
07/02/2019
Primary completion :
03/21/2023
Completion :
06/03/2026
EGFR
|
EGFR mutation • EGFR L858R • EGFR T790M • EGFR exon 19 deletion
|
cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed
Phase 2
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
09/23/2021
Initiation :
01/27/2021
Primary completion :
02/01/2023
Completion :
02/01/2023
EGFR • ALK • CTLA4
|
EGFR mutation • ALK mutation
|
Imfinzi (durvalumab)
Phase 1a/1b
Boehringer Ingelheim
Active, not recruiting
Last update posted :
09/23/2021
Initiation :
07/08/2015
Primary completion :
11/01/2021
Completion :
12/01/2021
EGFR
|
BI 894999
Phase 3
Amgen
Active, not recruiting
Last update posted :
09/23/2021
Initiation :
06/04/2020
Primary completion :
11/02/2021
Completion :
04/27/2026
KRAS
|
KRAS mutation • KRAS G12C • KRAS G12
|
docetaxel • Lumakras (sotorasib)
Phase 1
Novartis Pharmaceuticals
Active, not recruiting
Last update posted :
09/23/2021
Initiation :
01/18/2016
Primary completion :
11/04/2021
Completion :
11/04/2021
KRAS • NRAS • DUSP6
|
KRAS mutation • NRAS mutation
|
spartalizumab (PDR001) • naporafenib (LXH254)
Phase 1/2
Sanofi
Active, not recruiting
Last update posted :
09/23/2021
Initiation :
07/23/2014
Primary completion :
03/31/2022
Completion :
03/31/2022
CEACAM5
|
CEACAM5 positive • CEACAM5 expression
|
tusamitamab ravtansine (SAR408701)
Phase 3
Hoffmann-La Roche
Recruiting
Last update posted :
09/23/2021
Initiation :
04/09/2020
Primary completion :
09/15/2022
Completion :
02/07/2023
EGFR • PD-L1 • ALK
|
PD-L1 expression • EGFR mutation • EGFR T790M • ALK rearrangement
|
Avastin (bevacizumab) • carboplatin • Tecentriq (atezolizumab) • paclitaxel • pemetrexed
Phase N/A
Amgen
Available
Last update posted :
09/23/2021
PD-L1 • KRAS
|
KRAS mutation • KRAS G12C • KRAS G12
|
Lumakras (sotorasib)
Phase 3
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/23/2021
Initiation :
05/28/2019
Primary completion :
12/28/2026
Completion :
12/28/2026
TMB
|
cisplatin • carboplatin • Tecentriq (atezolizumab) • etoposide IV
Phase 3
Merck Sharp & Dohme Corp.
Recruiting
Last update posted :
09/23/2021
Initiation :
12/08/2020
Primary completion :
10/28/2027
Completion :
10/28/2027
PD-L1
|
PD-L1 expression
|
Keytruda (pembrolizumab) • Lynparza (olaparib) • etoposide IV
Phase 2
Centre hospitalier de l'Université de Montréal ...
Not yet recruiting
Last update posted :
09/23/2021
Initiation :
11/01/2021
Primary completion :
09/01/2024
Completion :
09/01/2025
PD-L1
|
PD-L1 expression
|
Opdivo (nivolumab)
Phase 1/2
National Cancer Institute (NCI)
Not yet recruiting
Last update posted :
09/23/2021
Initiation :
09/28/2021
Primary completion :
12/30/2027
Completion :
12/30/2028
PD-L1
|
PD-L1 expression
|
azacitidine • bintrafusp alfa (M7824)
Phase 3
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/23/2021
Initiation :
06/03/2020
Primary completion :
12/15/2024
Completion :
12/15/2024
EGFR • PD-L1
|
PD-L1 expression
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel • gemcitabine • pemetrexed • liposomal gemcitabine (FF-10832)
Phase 1/2
Hoffmann-La Roche
Recruiting
Last update posted :
09/23/2021
Initiation :
01/02/2018
Primary completion :
06/01/2022
Completion :
11/14/2023
PD-L1
|
PD-L1 expression
|
Avastin (bevacizumab) • carboplatin • Tecentriq (atezolizumab) • gemcitabine • docetaxel • Cotellic (cobimetinib) • pemetrexed • ipatasertib (GDC-0068) • Trodelvy (sacituzumab govitecan-hziy) • Repatha (evolocumab) • Actemra IV (tocilizumab) • Tradjenta (linagliptin) • cibisatamab (RG7802) • ciforadenant (CPI-444)
Phase N/A
Hoffmann-La Roche
Recruiting
Last update posted :
09/23/2021
Initiation :
02/07/2019
Primary completion :
12/19/2026
Completion :
12/19/2026
EGFR • PD-L1 • ALK
|
PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK positive • ALK mutation
|
Tecentriq (atezolizumab)
Phase 2
Duke University
Recruiting
Last update posted :
09/23/2021
Initiation :
06/30/2018
Primary completion :
06/30/2022
Completion :
06/30/2024
EGFR
|
EGFR mutation • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation
|
Tagrisso (osimertinib)
Phase N/A
Dana-Farber Cancer Institute
Active, not recruiting
Last update posted :
09/23/2021
Initiation :
12/28/2012
Primary completion :
11/07/2018
Completion :
03/31/2022
EGFR
|
EGFR mutation • EGFR T790M • EGFR expression • EGFR R776H
Phase 1
Boehringer Ingelheim
Recruiting
Last update posted :
09/23/2021
Initiation :
05/03/2018
Primary completion :
03/01/2023
Completion :
07/04/2023
PD-L1
|
PD-L1 expression
|
BI 836880 • ezabenlimab (BI 754091)
Phase 3
Hoffmann-La Roche
Recruiting
Last update posted :
09/23/2021
Initiation :
12/27/2018
Primary completion :
06/30/2022
Completion :
03/31/2024
EGFR
|
Tecentriq (atezolizumab) • Tecentriq SC (atezolizumab SC) • Lispro-PH20 (insulin lispro/rHuPH20)
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/23/2021
Initiation :
04/26/2016
Primary completion :
12/31/2021
EGFR • HER-2 • ER • PGR
|
HER-2 expression • ALK mutation
|
Lynparza (olaparib) • Recentin (cediranib)
Phase 3
BeiGene
Recruiting
Last update posted :
09/23/2021
Initiation :
07/27/2021
Primary completion :
06/30/2024
Completion :
06/30/2024
ALK • ROS1
|
PD-L1 expression • ALK rearrangement • ROS1 rearrangement
|
docetaxel • Baize’an (tislelizumab) • sitravatinib (MGCD516)
Phase 1
Rhizen Pharmaceuticals SA
Recruiting
Last update posted :
09/23/2021
Initiation :
09/01/2021
Primary completion :
05/01/2023
Completion :
08/01/2023
HRD
|
RP12146
Phase 1
Merck Sharp & Dohme Corp.
Recruiting
Last update posted :
09/23/2021
Initiation :
06/26/2019
Primary completion :
05/09/2025
Completion :
05/09/2025
EGFR • KRAS • ALK • MSI
|
KRAS mutation • EGFR mutation
|
Keytruda (pembrolizumab) • mRNA-5671
Phase 2
Revolution Medicines, Inc.
Not yet recruiting
Last update posted :
09/23/2021
Initiation :
10/01/2021
Primary completion :
03/31/2023
Completion :
01/19/2024
KRAS
|
Lumakras (sotorasib) • SAR442720
Phase 1b/2
Pfizer
Recruiting
Last update posted :
09/22/2021
Initiation :
11/10/2020
Primary completion :
12/20/2025
Completion :
12/20/2025
PD-L1
|
PD-L1 expression • BRAF V600E • BRAF V600
|
Braftovi (encorafenib) • Mektovi (binimetinib) • Inlyta (axitinib) • sasanlimab (PF-06801591) • SGN-TGT
Phase 1
Xencor, Inc.
Recruiting
Last update posted :
09/22/2021
Initiation :
05/01/2019
Primary completion :
07/01/2023
Completion :
12/01/2024
HER-2 • ER • PGR
|
HER-2 negative
|
Yervoy (ipilimumab) • izuralimab (XmAb23104)
Phase 1
Sichuan University
Active, not recruiting
Last update posted :
09/22/2021
Initiation :
03/12/2021
Primary completion :
01/01/2023
Completion :
01/01/2024
HER-2
|
HER-2 expression
Phase 3
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/22/2021
Initiation :
10/22/2020
Primary completion :
09/01/2025
Completion :
09/01/2025
EGFR
|
EGFR mutation • EGFR L858R • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation
|
Avastin (bevacizumab) • Tagrisso (osimertinib) • Mvasi (bevacizumab biosimilar) • Zirabev (bevacizumab biosimilar) • Krabeva (bevacizumab biosimilar) • BP102 (bevacizumab biosimilar) • CT-P16 (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • HD204 (bevacizumab biosimilar) • HLX-04 (bevacizumab biosimilar) • LY01008 (bevacizumab biosimilar) • MIL 60 (bevacizumab biosimilar)
Phase 2
Incyte Corporation
Active, not recruiting
Last update posted :
09/22/2021
Initiation :
01/09/2019
Primary completion :
10/30/2020
Completion :
07/06/2022
PD-L1 • ALK
|
PD-L1 expression • PD-L1 overexpression
|
retifanlimab (INCMGA0012)
Phase N/A
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/22/2021
Initiation :
08/18/2014
Primary completion :
09/28/2026
EGFR • PD-L1 • ALK • PD-1 • CTLA4
|
ALK rearrangement
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Xalkori (crizotinib) • cisplatin • erlotinib • carboplatin • paclitaxel • gemcitabine • pemetrexed • CMAB 819 (nivolumab biosimilar) • liposomal gemcitabine (FF-10832)
Phase 1/2
Xcovery Holding Company, LLC
Completed
Last update posted :
09/22/2021
Initiation :
06/01/2012
Primary completion :
09/17/2020
Completion :
09/17/2020
ALK
|
ALK mutation
|
ensartinib (X-396)
Phase 2
EMD Serono Research & Development Institute, Inc.
Active, not recruiting
Last update posted :
09/22/2021
Initiation :
09/13/2016
Primary completion :
12/09/2021
Completion :
02/28/2023
MET
|
Tepmetko (tepotinib)
Phase 2
Spanish Lung Cancer Group
Active, not recruiting
Last update posted :
09/22/2021
Initiation :
07/07/2018
Primary completion :
12/30/2021
Completion :
12/15/2022
EGFR • ALK
|
EGFR mutation • ALK fusion
|
carboplatin • Tecentriq (atezolizumab) • pemetrexed
Phase 1
Incyte Corporation
Active, not recruiting
Last update posted :
09/22/2021
Initiation :
09/24/2018
Primary completion :
09/30/2021
Completion :
09/30/2021
HAVCR2
|
INCAGN2390
Phase 3
Hoffmann-La Roche
Active, not recruiting
Last update posted :
09/22/2021
Initiation :
04/24/2018
Primary completion :
04/20/2025
Completion :
04/20/2026
PD-L1
|
IRF1 expression
|
cisplatin • carboplatin • Tecentriq (atezolizumab) • gemcitabine • Abraxane (albumin-bound paclitaxel) • pemetrexed
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/22/2021
Initiation :
01/13/2017
Primary completion :
08/01/2022
Completion :
08/01/2022
CD4
|
PD-L1 overexpression • PD-L1 amplification
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)
Phase 1/2
M.D. Anderson Cancer Center
Completed
Last update posted :
09/22/2021
Initiation :
03/31/2015
Primary completion :
09/16/2021
Completion :
09/16/2021
EGFR • HER-2
|
EGFR mutation
|
ibrutinib
Phase 1
EMD Serono Research & Development Institute, Inc.
Recruiting
Last update posted :
09/22/2021
Initiation :
01/13/2021
Primary completion :
07/15/2023
Completion :
03/27/2024
EGFR • MSI • MUC1
|
MSI-H/dMMR • EGFR expression • MUC1 expression
|
M1231
Phase 3
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/22/2021
Initiation :
07/18/2018
Primary completion :
10/01/2025
Completion :
10/01/2025
LINS1
|
Albumin-L
|
Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
Phase 1/2
InventisBio Inc.
Recruiting
Last update posted :
09/22/2021
Initiation :
10/02/2020
Primary completion :
11/01/2022
Completion :
02/01/2023
KRAS
|
KRAS mutation • KRAS G12C • KRAS G12
|
D-1553
Phase 1
Boehringer Ingelheim
Recruiting
Last update posted :
09/22/2021
Initiation :
05/04/2017
Primary completion :
03/28/2023
Completion :
08/24/2023
EGFR • HER-2 • ALK • ER • PGR
|
EGFR mutation • HER-2 negative • ALK translocation
|
Verzenio (abemaciclib) • fulvestrant • letrozole • anastrozole • xentuzumab (BI-836845)
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/22/2021
Initiation :
05/09/2016
Primary completion :
07/01/2023
Completion :
12/31/2027
BRCA
|
Lynparza (olaparib) • irinotecan
Phase 3
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/22/2021
Initiation :
02/28/2019
Primary completion :
09/30/2021
Completion :
09/30/2021
EGFR • BRAF • PD-L1 • ALK • ROS1
|
PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • ALK translocation
|
Keytruda (pembrolizumab) • carboplatin • pemetrexed
Phase 1/2
Takeda
Recruiting
Last update posted :
09/22/2021
Initiation :
03/08/2021
Primary completion :
11/01/2023
Completion :
10/01/2024
EGFR • PD-L1 • ALK
|
EGFR mutation • EGFR expression • ALK rearrangement
|
MVC-101
Phase 1
AO GENERIUM
Recruiting
Last update posted :
09/22/2021
Initiation :
07/22/2020
Primary completion :
04/22/2024
Completion :
06/15/2024
PD-1
|
GNR-051
Phase 2
Novartis Pharmaceuticals
Active, not recruiting
Last update posted :
09/22/2021
Initiation :
08/19/2020
Primary completion :
05/14/2026
Completion :
03/07/2029
EGFR • PD-L1 • ALK
|
PD-L1 expression • ALK rearrangement • MET mutation
|
spartalizumab (PDR001) • Tabrecta (capmatinib)
Phase 2
Spanish Lung Cancer Group
Recruiting
Last update posted :
09/22/2021
Initiation :
05/07/2018
Primary completion :
01/30/2023
Completion :
10/30/2023
HRAS
|
HRAS mutation
|
Zarnestra (tipifarnib)
Phase 1/2
Hoffmann-La Roche
Recruiting
Last update posted :
09/22/2021
Initiation :
03/17/2017
Primary completion :
12/31/2021
Completion :
02/29/2024
RET • CEACAM5
|
RET fusion • RET mutation • RET rearrangement
|
Gavreto (pralsetinib)
Phase 2
AstraZeneca
Recruiting
Last update posted :
09/22/2021
Initiation :
09/28/2020
Primary completion :
02/10/2023
Completion :
02/12/2024
EGFR • MET
|
EGFR mutation • EGFR L858R • MET amplification • EGFR exon 19 deletion
|
Tagrisso (osimertinib) • Orpathys (savolitinib)
Phase 3
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/22/2021
Initiation :
04/09/2020
Primary completion :
10/31/2028
Completion :
10/31/2028
CD4
|
cisplatin • carboplatin • paclitaxel • Imfinzi (durvalumab) • etoposide IV • pemetrexed
Phase 3
Bristol-Myers Squibb
Recruiting
Last update posted :
09/21/2021
Initiation :
08/05/2015
Primary completion :
08/28/2024
Completion :
08/30/2024
PD-L1
|
Opdivo (nivolumab) • cisplatin • carboplatin • Yervoy (ipilimumab) • paclitaxel • gemcitabine • pemetrexed
Phase 1a/1b
Eli Lilly and Company
Recruiting
Last update posted :
09/21/2021
Initiation :
07/19/2021
Primary completion :
10/01/2023
Completion :
10/01/2023
KRAS
|
KRAS mutation • KRAS G12C • KRAS G12
|
Erbitux (cetuximab) • erlotinib • Verzenio (abemaciclib) • Tyvyt (sintilimab) • temuterkib (LY3214996) • LY3537982 • erbumine (LY3295668)
Phase 2
Seagen Inc.
Recruiting
Last update posted :
09/21/2021
Initiation :
01/11/2021
Primary completion :
01/31/2023
Completion :
05/31/2025
HER-2
|
HER-2 amplification • HER-2 overexpression • HER-2 mutation
|
Herceptin (trastuzumab) • fulvestrant • Tukysa (tucatinib)
Phase 1/2
H. Lee Moffitt Cancer Center and Research Insti...
Active, not recruiting
Last update posted :
09/21/2021
Initiation :
02/02/2018
Primary completion :
02/01/2022
Completion :
02/01/2023
EGFR • BRAF • ALK
|
BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • ALK rearrangement • ROS1 rearrangement
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • nintedanib
Phase 1b
Astellas Pharma Global Development, Inc.
Active, not recruiting
Last update posted :
09/21/2021
Initiation :
09/08/2017
Primary completion :
03/31/2022
Completion :
06/30/2022
EGFR • ALK
|
EGFR mutation • ALK positive • ALK mutation
|
Keytruda (pembrolizumab) • ASP8374
Phase 1
Seagen Inc.
Recruiting
Last update posted :
09/21/2021
Initiation :
01/18/2021
Primary completion :
12/31/2022
Completion :
12/31/2023
HER-2
|
HER-2 negative
|
SGN-STNV
Phase 1b
Daiichi Sankyo, Inc.
Recruiting
Last update posted :
09/21/2021
Initiation :
11/06/2020
Primary completion :
03/15/2023
Completion :
12/17/2024
EGFR • BRAF • ALK • PD-L2 • CTLA4 • TROP2 • NTRK
|
TROP2 expression
|
cisplatin • carboplatin • Imfinzi (durvalumab) • datopotamab deruxtecan (DS-1062a)
Phase 2
G1 Therapeutics, Inc.
Recruiting
Last update posted :
09/21/2021
Initiation :
04/16/2021
Primary completion :
03/31/2024
Completion :
03/31/2024
EGFR • PD-L1 • ALK • ROS1 • PD-1
|
docetaxel • Cosela (trilaciclib)
Phase 1/2
Loxo Oncology, Inc.
Recruiting
Last update posted :
09/21/2021
Initiation :
05/02/2017
Primary completion :
11/21/2022
Completion :
11/21/2023
RET
|
Retevmo (selpercatinib)
Phase 1
Seagen Inc.
Active, not recruiting
Last update posted :
09/21/2021
Initiation :
02/28/2015
Primary completion :
02/28/2022
Completion :
02/29/2024
CD40
|
Keytruda (pembrolizumab) • gemcitabine • Abraxane (albumin-bound paclitaxel) • SEA-CD40
Phase 2
Astellas Pharma Global Development, Inc.
Recruiting
Last update posted :
09/21/2021
Initiation :
03/09/2020
Primary completion :
07/31/2023
Completion :
07/31/2023
BRAF • ALK • ER • PGR
|
PD-L1 expression • HER-2 positive • EGFR mutation • BRAF mutation • ER positive • HER-2 negative • ER negative • PGR negative
|
Padcev (enfortumab vedotin)
Phase 1
Pfizer
Recruiting
Last update posted :
09/21/2021
Initiation :
09/24/2020
Primary completion :
12/25/2023
Completion :
12/25/2023
PD-L1
|
PD-L1 expression
|
Inlyta (axitinib) • sasanlimab (PF-06801591) • PF-07265807
Phase 1b
Daiichi Sankyo, Inc.
Recruiting
Last update posted :
09/21/2021
Initiation :
09/15/2020
Primary completion :
12/15/2022
Completion :
10/01/2024
EGFR • BRAF • ALK • PD-L2 • TROP2 • NTRK
|
TROP2 expression
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • datopotamab deruxtecan (DS-1062a)
Phase 1/2
Elucida Oncology
Recruiting
Last update posted :
09/21/2021
Initiation :
09/13/2021
Primary completion :
03/15/2024
Completion :
03/15/2025
FOLR1
|
ELU001
Phase 3
Loxo Oncology, Inc.
Recruiting
Last update posted :
09/21/2021
Initiation :
02/17/2020
Primary completion :
01/15/2023
Completion :
08/18/2025
RET
|
RET fusion • RET positive
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • Retevmo (selpercatinib)
Phase 1/2
Bicycle Tx Limited
Recruiting
Last update posted :
09/21/2021
Initiation :
11/07/2019
Primary completion :
12/31/2022
Completion :
12/31/2023
EPHA2
|
Opdivo (nivolumab) • BT5528
Phase 1/2
Astellas Pharma Global Development, Inc.
Recruiting
Last update posted :
09/21/2021
Initiation :
07/29/2021
Primary completion :
12/31/2027
Completion :
12/31/2027
EGFR • BRAF • ALK • WT1
|
EGFR mutation • ALK positive • ALK mutation
|
Keytruda (pembrolizumab) • ASP7517
Phase 1a/1b
OncoC4, Inc.
Recruiting
Last update posted :
09/21/2021
Initiation :
09/16/2020
Primary completion :
12/31/2022
Completion :
12/31/2023
EGFR
|
EGFR mutation
|
Keytruda (pembrolizumab) • Tagrisso (osimertinib) • ONC-392
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/21/2021
Initiation :
08/29/2019
Primary completion :
12/01/2021
Completion :
07/01/2023
MSLN
|
MSLN expression
|
Xeljanz (tofacitinib) • LMB-100
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/21/2021
Initiation :
11/04/2020
Primary completion :
11/02/2025
Completion :
11/02/2025
CD4
|
Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CMAB 819 (nivolumab biosimilar)
Phase 3
Loxo Oncology, Inc.
Not yet recruiting
Last update posted :
09/21/2021
Initiation :
10/31/2021
Primary completion :
08/31/2028
Completion :
11/30/2032
RET
|
RET fusion
|
Retevmo (selpercatinib)
Phase 1/2
Sanofi
Recruiting
Last update posted :
09/21/2021
Initiation :
06/16/2020
Primary completion :
07/15/2025
Completion :
07/15/2025
BRAF • KRAS • NF1
|
KRAS mutation • BRAF mutation • NF1 mutation • BRAF amplification
|
Keytruda (pembrolizumab) • SAR442720
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/20/2021
Initiation :
04/04/2019
Primary completion :
08/31/2022
Completion :
08/31/2022
MSI • IL2
|
Opdivo (nivolumab) • CMAB 819 (nivolumab biosimilar)
Phase 3
Yuhan Corporation
Recruiting
Last update posted :
09/20/2021
Initiation :
02/13/2020
Primary completion :
12/01/2022
Completion :
06/01/2024
EGFR
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion
|
gefitinib • Leclaza (lazertinib) • SER-301
Phase 1/2
AstraZeneca
Recruiting
Last update posted :
09/20/2021
Initiation :
10/31/2014
Primary completion :
10/30/2024
Completion :
10/30/2024
HER-2 • ATM • HRD • RAD51C • RAD51D • BRCA
|
HER-2 negative • HRD • BRCA mutation • RAD51 mutation
|
Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • ceralasertib (AZD6738)
Phase 1/2
Achilles Therapeutics UK Limited
Recruiting
Last update posted :
09/20/2021
Initiation :
07/08/2019
Primary completion :
07/01/2023
Completion :
12/31/2023
PD-L1
|
Keytruda (pembrolizumab) • ATL 001
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/20/2021
Initiation :
04/08/2020
Primary completion :
12/31/2023
Completion :
12/31/2024
BRCA
|
Rubraca (rucaparib) • PLX038 • firtecan pegol (PEG-SN38)
Phase 3
Merck Sharp & Dohme Corp.
Recruiting
Last update posted :
09/20/2021
Initiation :
04/07/2021
Primary completion :
04/04/2025
Completion :
04/29/2027
EGFR • PD-L1 • ALK • ROS1 • PD-1
|
PD-L1 expression
|
Keytruda (pembrolizumab) • vibostolimab (MK-7684) • vibostolimab/pembrolizumab (MK-7684A)
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/20/2021
Initiation :
04/12/2019
Primary completion :
02/28/2023
Completion :
02/28/2023
PD-L1 • CD4
|
Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)
Phase 2
Betta Pharmaceuticals Co., Ltd.
Recruiting
Last update posted :
09/20/2021
Initiation :
08/12/2021
Primary completion :
12/31/2023
Completion :
12/31/2024
EGFR
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion
|
Conmana (icotinib) • befotertinib (D-0316)
Phase 3
PrECOG, LLC.
Recruiting
Last update posted :
09/20/2021
Initiation :
02/18/2021
Primary completion :
04/01/2025
Completion :
12/01/2025
PD-L1
|
cisplatin • carboplatin • Imfinzi (durvalumab) • pemetrexed
Phase 2
Verastem, Inc.
Recruiting
Last update posted :
09/20/2021
Initiation :
12/31/2020
Primary completion :
03/01/2023
Completion :
12/01/2025
KRAS
|
KRAS mutation
|
VS-6766 • defactinib (VS-6063)
Phase 3
Hoffmann-La Roche
Recruiting
Last update posted :
09/20/2021
Initiation :
08/16/2018
Primary completion :
06/30/2023
Completion :
11/19/2026
ALK
|
ALK positive
|
cisplatin • carboplatin • gemcitabine • Alecensa (alectinib) • pemetrexed • vinorelbine tartrate
Phase 2/3
National Cancer Institute (NCI)
Not yet recruiting
Last update posted :
09/20/2021
Initiation :
01/06/2022
Primary completion :
12/31/2027
Completion :
12/31/2027
EGFR • PD-L1 • ALK • ROS1
|
PD-L1 expression • ALK mutation • ROS1 mutation
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • carboplatin • Yervoy (ipilimumab) • paclitaxel • Abraxane (albumin-bound paclitaxel) • pemetrexed
Phase 1/2
Vanderbilt-Ingram Cancer Center
Recruiting
Last update posted :
09/20/2021
Initiation :
07/10/2018
Primary completion :
07/01/2023
Completion :
07/01/2024
EGFR • BRAF • PD-L1 • ROS1
|
Opdivo (nivolumab) • vorolanib (X-82)
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/20/2021
Initiation :
06/01/2020
Primary completion :
08/15/2023
Completion :
08/15/2023
ATM
|
Keytruda (pembrolizumab) • carboplatin • gemcitabine • Bavencio (avelumab) • berzosertib (M6620) • liposomal gemcitabine (FF-10832)
Phase 2
Merck Sharp & Dohme Corp.
Recruiting
Last update posted :
09/20/2021
Initiation :
04/20/2021
Primary completion :
05/17/2023
Completion :
08/13/2027
EGFR • ALK
|
Keytruda (pembrolizumab) • docetaxel • vibostolimab (MK-7684) • vibostolimab/pembrolizumab (MK-7684A)
Phase 2
Puma Biotechnology, Inc.
Recruiting
Last update posted :
09/20/2021
Initiation :
09/30/2013
Primary completion :
03/30/2022
Completion :
09/30/2022
EGFR • HER-2
|
EGFR mutation • HER-2 negative • HER-2 mutation • EGFR exon 18 mutation
|
Herceptin (trastuzumab) • paclitaxel • Nerlynx (neratinib) • fulvestrant
Phase 2
Genentech, Inc.
Recruiting
Last update posted :
09/20/2021
Initiation :
11/06/2020
Primary completion :
08/15/2028
Completion :
08/15/2028
BRAF • ALK • RET • NTRK1 • NTRK3 • ROS1 • NTRK2
|
BRAF mutation • BRAF V600 • NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • RET fusion • ALK fusion • RET mutation • ROS1 fusion • ALK-ROS1 fusion
|
Zelboraf (vemurafenib) • Rozlytrek (entrectinib) • Cotellic (cobimetinib) • Alecensa (alectinib) • Gavreto (pralsetinib)
Phase 1/2
Nektar Therapeutics
Recruiting
Last update posted :
09/20/2021
Initiation :
06/09/2017
Primary completion :
09/01/2023
Completion :
01/01/2024
PD-L1
|
PD-L1 expression
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • Abraxane (albumin-bound paclitaxel) • pemetrexed • bempegaldesleukin (NKTR-214)
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/20/2021
Initiation :
06/29/2015
Primary completion :
01/29/2022
Completion :
12/29/2022
EGFR • HER-2 • BRAF • ALK • BRCA2 • PGR • BRCA1
|
PD-L1 expression • BRAF V600E • BRCA1 mutation • BRCA2 mutation • EGFR mutation • BRAF V600 • ALK translocation • BRCA1 mutation + BRCA2 mutation
|
Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/20/2021
Initiation :
05/22/2020
Primary completion :
05/01/2022
Completion :
05/01/2022
PD-L1 • ALK • RET • ROS1
|
EGFR L858R • MET amplification • EGFR exon 19 deletion • ALK rearrangement • MET exon 14 mutation • EGFR L861Q • RET rearrangement • EGFR G719X • EGFR negative • MET-H
|
Opdivo (nivolumab) • gemcitabine • docetaxel • Abraxane (albumin-bound paclitaxel) • Cyramza (ramucirumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CMAB 819 (nivolumab biosimilar) • lexatumumab (ETR2-ST01) • liposomal gemcitabine (FF-10832)
Phase 1
Ruijin Hospital
Recruiting
Last update posted :
09/17/2021
Initiation :
10/01/2021
Primary completion :
01/09/2022
Completion :
07/09/2022
MSLN
|
MSLN positive
|
anti-mesothelin gene engineered lymphocytes
Phase 3
Merck Sharp & Dohme Corp.
Recruiting
Last update posted :
09/17/2021
Initiation :
10/23/2019
Primary completion :
03/04/2024
Completion :
11/23/2025
PD-L1
|
PD-L1 expression
|
Keytruda (pembrolizumab) • lenvatinib
Phase 3
AstraZeneca
Not yet recruiting
Last update posted :
09/17/2021
Initiation :
10/29/2021
Primary completion :
01/17/2025
Completion :
03/01/2027
HER-2
|
HER-2 mutation
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • Enhertu (fam-trastuzumab deruxtecan-nxki) • pemetrexed
Phase 3
Janssen Research & Development, LLC
Recruiting
Last update posted :
09/17/2021
Initiation :
10/13/2020
Primary completion :
01/12/2022
Completion :
11/08/2024
EGFR
|
EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
|
carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw)
Phase 3
Janssen Research & Development, LLC
Not yet recruiting
Last update posted :
09/17/2021
Initiation :
11/17/2021
Primary completion :
05/31/2023
Completion :
11/30/2025
EGFR
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion
|
Tagrisso (osimertinib) • carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
Phase 1
Syros Pharmaceuticals
Recruiting
Last update posted :
09/17/2021
Initiation :
01/23/2020
Primary completion :
07/01/2023
Completion :
07/01/2024
HER-2
|
HR positive • HER-2 negative
|
fulvestrant • SY-5609
Phase 2
Washington University School of Medicine
Recruiting
Last update posted :
09/17/2021
Initiation :
08/04/2021
Primary completion :
11/30/2023
Completion :
02/28/2028
PD-L1
|
PD-L1 expression
|
zimberelimab (AB122) • domvanalimab (AB154) • etrumadenant (AB928)
Phase 1
Daiichi Sankyo, Inc.
Active, not recruiting
Last update posted :
09/17/2021
Initiation :
10/30/2017
Primary completion :
12/31/2021
Completion :
12/31/2023
ALK • ROS1
|
EGFR L858R • EGFR exon 19 deletion • ALK fusion • EGFR L861Q • ROS1 fusion • EGFR G719X • ALK-ROS1 fusion
|
patritumab deruxtecan (U3-1402)
Phase 3
Janssen Research & Development, LLC
Recruiting
Last update posted :
09/17/2021
Initiation :
09/30/2020
Primary completion :
04/30/2024
Completion :
03/30/2026
EGFR
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion
|
Tagrisso (osimertinib) • Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/17/2021
Initiation :
06/15/2020
Primary completion :
11/30/2025
Completion :
11/30/2025
SLFN11
|
Tecentriq (atezolizumab) • Talzenna (talazoparib)
Phase 
Groupe Francais De Pneumo-Cancerologie
Recruiting
Last update posted :
09/17/2021
Initiation :
12/18/2020
Primary completion :
06/30/2027
Completion :
06/30/2027
HER-2 • PD-L1 • ALK • RET • NTRK
|
PD-L1 expression • EGFR mutation
Phase 1
Emory University
Recruiting
Last update posted :
09/17/2021
Initiation :
08/24/2020
Primary completion :
08/01/2022
Completion :
08/01/2022
IL6 • CXCL8 • TNFA • IL2 • CSF2 • IL10 • IL1A • IL1B
|
ketorolac ophthalmic
Phase 1
Merck Sharp & Dohme Corp.
Recruiting
Last update posted :
09/17/2021
Initiation :
07/11/2018
Primary completion :
11/18/2024
Completion :
11/18/2024
HER-2
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel • lenvatinib • pemetrexed • MK-4830
Phase 3
AstraZeneca
Active, not recruiting
Last update posted :
09/17/2021
Initiation :
09/27/2018
Primary completion :
05/10/2024
Completion :
05/10/2024
PD-L1
|
PD-L1 expression • PD-L1 negative
|
Imfinzi (durvalumab) • tremelimumab (CP-675206)
Phase 2
Hoffmann-La Roche
Active, not recruiting
Last update posted :
09/17/2021
Initiation :
09/09/2020
Primary completion :
07/16/2021
Completion :
06/30/2023
EGFR
|
PD-L1 expression • EGFR mutation • EGFR T790M
|
Avastin (bevacizumab) • Tecentriq (atezolizumab)
Phase 1
Janssen Research & Development, LLC
Recruiting
Last update posted :
09/17/2021
Initiation :
05/24/2016
Primary completion :
01/15/2024
Completion :
01/15/2024
ALK • MET
|
EGFR mutation • EGFR L858R • MET amplification • EGFR exon 19 deletion • EGFR exon 20 insertion • MET exon 14 mutation • EGFR C797S • MET mutation • EGFR exon 20 mutation • MET expression
|
carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
Phase 
Wuhan Union Hospital, China
Not yet recruiting
Last update posted :
09/16/2021
Initiation :
10/01/2021
Primary completion :
12/01/2023
Completion :
12/01/2024
B2M • CEACAM5 • MUC1 • KRT19 • CRP
Phase 1
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
09/16/2021
Initiation :
10/28/2013
Primary completion :
11/03/2017
KRAS
|
KRAS mutation • KRAS G13 • KRAS G12 • KRAS Q61
|
Mekinist (trametinib) • carboplatin • paclitaxel
Phase 3
Hoffmann-La Roche
Active, not recruiting
Last update posted :
09/16/2021
Initiation :
07/03/2019
Primary completion :
08/31/2022
Completion :
08/31/2022
EGFR • ALK
|
EGFR mutation • ALK fusion
|
Tecentriq (atezolizumab)
Phase 3
AstraZeneca
Active, not recruiting
Last update posted :
09/16/2021
Initiation :
12/03/2014
Primary completion :
06/19/2017
Completion :
12/31/2021
EGFR
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion
|
erlotinib • Tagrisso (osimertinib) • gefitinib
Phase 1/2
RemeGen Co., Ltd.
Recruiting
Last update posted :
09/16/2021
Initiation :
09/26/2018
Primary completion :
09/30/2021
Completion :
12/30/2021
HER-2 • MET
|
EGFR mutation • HER-2 overexpression • MET amplification • EGFR T790M • HER-2 mutation • MET mutation • HER-2 exon 20 mutation
|
Aidixi (disitamab vedotin)
Phase 1/2
UNICANCER
Active, not recruiting
Last update posted :
09/16/2021
Initiation :
06/20/2018
Primary completion :
01/14/2022
Completion :
12/30/2024
TMB
|
Imfinzi (durvalumab) • tremelimumab (CP-675206) • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)
Phase 3
Merck Sharp & Dohme Corp.
Recruiting
Last update posted :
09/16/2021
Initiation :
04/24/2018
Primary completion :
01/20/2024
Completion :
06/29/2026
PD-L1
|
Keytruda (pembrolizumab) • cisplatin • gemcitabine • pemetrexed
Phase 3
Merck Sharp & Dohme Corp.
Recruiting
Last update posted :
09/16/2021
Initiation :
08/05/2021
Primary completion :
02/10/2023
Completion :
10/14/2026
EGFR • ALK • ROS1
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • Abraxane (albumin-bound paclitaxel) • pemetrexed
Phase 1
Janssen Research & Development, LLC
Not yet recruiting
Last update posted :
09/16/2021
Initiation :
10/18/2021
Primary completion :
02/22/2024
Completion :
02/22/2024
MSI
|
MSI-H/dMMR
|
JNJ-78306358
Phase 1
AstraZeneca
Recruiting
Last update posted :
09/16/2021
Initiation :
03/09/2021
Primary completion :
12/13/2023
Completion :
12/13/2023
EGFR • HER-2 • ALK • EML4
|
EGFR mutation • EML4-ALK fusion • ALK fusion
|
cisplatin • carboplatin • Imfinzi (durvalumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • pemetrexed
Phase 2
Novartis Pharmaceuticals
Recruiting
Last update posted :
09/16/2021
Initiation :
08/28/2017
Primary completion :
03/31/2022
Completion :
06/17/2022
EGFR • BRAF
|
BRAF V600E • EGFR mutation • EGFR T790M
|
spartalizumab (PDR001) • taminadenant (NIR178)
Phase 2
University of Michigan Rogel Cancer Center
Active, not recruiting
Last update posted :
09/16/2021
Initiation :
10/03/2017
Primary completion :
11/01/2022
Completion :
11/01/2022
EGFR • PD-L1
|
EGFR mutation
|
Keytruda (pembrolizumab) • carboplatin • pemetrexed
Phase 3
Merck Sharp & Dohme Corp.
Recruiting
Last update posted :
09/16/2021
Initiation :
06/26/2019
Primary completion :
08/21/2023
Completion :
02/23/2026
EGFR • KRAS • ALK • ROS1
|
KRAS mutation
|
Keytruda (pembrolizumab) • docetaxel • lenvatinib
Phase 1
Pacylex Pharmaceuticals
Recruiting
Last update posted :
09/16/2021
Initiation :
09/14/2021
Primary completion :
05/31/2022
Completion :
03/31/2023
CD20
|
CD20 expression
|
PCLX-001
Phase 1/2
Helsinn Healthcare SA
Recruiting
Last update posted :
09/16/2021
Initiation :
12/16/2020
Primary completion :
12/01/2023
Completion :
08/01/2024
RET
|
RET fusion
|
HM06
Phase 1
Amgen
Recruiting
Last update posted :
09/16/2021
Initiation :
04/29/2021
Primary completion :
10/06/2024
Completion :
10/06/2024
MSLN
|
MSLN expression • MSLN positive
|
zeluvalimab (AMG 404)
Phase 2
Masonic Cancer Center, University of Minnesota
Recruiting
Last update posted :
09/15/2021
Initiation :
09/27/2018
Primary completion :
02/01/2022
Completion :
02/01/2022
ALK • ER • ROS1
|
ALK rearrangement • ROS1 rearrangement • EGFR rearrangement
|
exemestane
Phase 2
Hoffmann-La Roche
Recruiting
Last update posted :
09/15/2021
Initiation :
01/18/2021
Primary completion :
09/25/2032
Completion :
09/25/2032
BRAF
|
Tecentriq (atezolizumab) • Rozlytrek (entrectinib) • Kadcyla (ado-trastuzumab emtansine) • Alecensa (alectinib) • Gavreto (pralsetinib) • ipatasertib (GDC-0068) • belvarafenib (HM95573) • idasanutlin (RO5503781) • inavolisib (GDC-0077)
Phase N/A
Lucence Health Inc.
Recruiting
Last update posted :
09/15/2021
Initiation :
04/05/2021
Primary completion :
09/30/2021
Completion :
11/30/2023
EGFR • HER-2 • BRAF • KRAS • ALK • ROS1 • NTRK
|
ROS1 fusion • NTRK fusion
Phase 1
Seagen Inc.
Recruiting
Last update posted :
09/15/2021
Initiation :
05/29/2020
Primary completion :
12/31/2022
Completion :
03/31/2023
TIGIT
|
sasanlimab (PF-06801591) • SGN-TGT
Phase 3
Sanofi
Recruiting
Last update posted :
09/15/2021
Initiation :
02/06/2020
Primary completion :
04/01/2022
Completion :
03/01/2024
CEACAM5
|
docetaxel • tusamitamab ravtansine (SAR408701)
Phase 2
University of Pennsylvania
Active, not recruiting
Last update posted :
09/15/2021
Initiation :
06/18/2018
Primary completion :
10/01/2021
Completion :
12/01/2021
PD-L1
|
PD-L1 expression
|
Keytruda (pembrolizumab) • itacitinib (INCB039110)
Phase 2
NeoImmuneTech
Recruiting
Last update posted :
09/15/2021
Initiation :
09/01/2021
Primary completion :
09/01/2023
Completion :
06/01/2024
PD-L1
|
PD-L1 expression
|
Tecentriq (atezolizumab) • Hyleukin-7 (efineptakin alfa)
Phase 1
Arcus Biosciences, Inc.
Recruiting
Last update posted :
09/15/2021
Initiation :
03/19/2021
Primary completion :
06/01/2023
Completion :
12/01/2023
PD-L1
|
PD-L1 expression • PD-L1 overexpression
|
zimberelimab (AB122) • AB308
Phase 1/2
Merck Sharp & Dohme Corp.
Recruiting
Last update posted :
09/15/2021
Initiation :
07/02/2017
Primary completion :
12/27/2023
Completion :
12/27/2023
EGFR • BRAF • ALK • CTLA4
|
BRAF V600E • BRAF V600 • ALK translocation
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • Abraxane (albumin-bound paclitaxel) • pemetrexed • quavonlimab (MK-1308) • quavonlimab/pembrolizumab (MK-1308A)
Phase 1a/1b
Boehringer Ingelheim
Recruiting
Last update posted :
09/15/2021
Initiation :
08/03/2021
Primary completion :
10/01/2024
Completion :
10/01/2024
KRAS
|
KRAS mutation • KRAS G12C • KRAS G12
|
BI 1701963 • BI 1823911 • midazolam hydrochloride
Phase 1
Boston Pharmaceuticals
Active, not recruiting
Last update posted :
09/15/2021
Initiation :
12/12/2018
Primary completion :
12/01/2021
Completion :
06/01/2022
RET
|
RET fusion • RET mutation
|
zeteletinib (BOS-172738)
Phase 2
M.D. Anderson Cancer Center
Not yet recruiting
Last update posted :
09/15/2021
Initiation :
12/16/2021
Primary completion :
12/30/2024
Completion :
12/30/2024
EGFR
|
EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
|
Cyramza (ramucirumab) • poziotinib (HM 78136B)
Phase 1
Infinity Pharmaceuticals, Inc.
Active, not recruiting
Last update posted :
09/15/2021
Initiation :
12/01/2015
Primary completion :
10/01/2021
Completion :
10/01/2022
HER-2 • ALK • ER • PGR • MSI
|
MSI-H/dMMR • ER negative • PGR negative
|
Opdivo (nivolumab) • eganelisib (IPI-549)
Phase 1
Bicara Therapeutics
Recruiting
Last update posted :
09/15/2021
Initiation :
06/01/2020
Primary completion :
12/31/2022
Completion :
06/01/2023
EGFR • PD-L1 • KRAS
|
KRAS mutation • EGFR mutation • KRAS G12D • EGFR amplification • PD-L1 negative • KRAS G13 • KRAS G12 • EGFR negative
|
Keytruda (pembrolizumab) • BCA101
Phase 2
Sichuan Cancer Hospital and Research Institute
Recruiting
Last update posted :
09/15/2021
Initiation :
04/01/2021
Primary completion :
04/01/2022
Completion :
03/31/2023
CD8
|
CD8 positive
|
carboplatin • paclitaxel
Phase 2
NovoCure GmbH
Recruiting
Last update posted :
09/14/2021
Initiation :
07/12/2021
Primary completion :
07/01/2024
Completion :
08/01/2024
EGFR • PD-L1 • ALK
|
PD-L1 expression • ALK translocation
|
Keytruda (pembrolizumab)
Phase 2/3
Sichuan Baili Pharmaceutical Co., Ltd.
Not yet recruiting
Last update posted :
09/14/2021
Initiation :
10/01/2021
Primary completion :
10/01/2023
Completion :
10/01/2023
EGFR • ALK
|
Tagrisso (osimertinib) • SI-B001
Phase N/A
Pfizer
Recruiting
Last update posted :
09/14/2021
Initiation :
08/02/2021
Primary completion :
12/31/2021
Completion :
12/31/2021
ALK
|
ALK rearrangement
|
Alecensa (alectinib) • Lorbrena (lorlatinib)
Phase N/A
AstraZeneca
Completed
Last update posted :
09/14/2021
Initiation :
09/05/2017
Primary completion :
10/28/2020
Completion :
10/28/2020
EGFR
|
EGFR mutation • EGFR T790M • EGFR exon 19 deletion
|
Tagrisso (osimertinib)
Phase 1
Boehringer Ingelheim
Recruiting
Last update posted :
09/14/2021
Initiation :
10/28/2019
Primary completion :
01/26/2022
Completion :
03/31/2022
KRAS
|
KRAS mutation
|
Mekinist (trametinib) • BI 1701963
Phase 1
AstraZeneca
Active, not recruiting
Last update posted :
09/14/2021
Initiation :
11/14/2014
Primary completion :
03/24/2015
Completion :
12/31/2021
EGFR
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X
|
Tagrisso (osimertinib)
Phase 3
Bio-Thera Solutions
Completed
Last update posted :
09/14/2021
Initiation :
10/20/2017
Primary completion :
11/05/2019
Completion :
05/27/2021
EGFR • ALK
|
EGFR mutation • ALK mutation
|
Avastin (bevacizumab) • carboplatin • paclitaxel • BAT1706 (bevacizumab biosimilar)
Phase 1a/1b
PsiOxus Therapeutics Ltd
Not yet recruiting
Last update posted :
09/14/2021
Initiation :
09/27/2021
Primary completion :
10/06/2022
Completion :
12/15/2022
MSI
|
MSI-H/dMMR
|
Opdivo (nivolumab) • NG-641
Phase 2
AbbVie
Recruiting
Last update posted :
09/14/2021
Initiation :
10/10/2018
Primary completion :
01/16/2025
Completion :
01/16/2025
EGFR • MET
|
EGFR mutation • MET expression
|
telisotuzumab vedotin (ABBV-399) • telisotuzumab (h224G11)
Phase 1
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
09/14/2021
Initiation :
03/01/2011
Primary completion :
06/01/2020
Completion :
06/01/2022
HER-2
|
Z-endoxifen hydrochloride
Phase 1
Roswell Park Cancer Institute
Not yet recruiting
Last update posted :
09/14/2021
Initiation :
10/01/2021
Primary completion :
10/01/2023
Completion :
10/01/2024
KRAS • CDK4
|
KRAS mutation
|
Ibrance (palbociclib) • Mektovi (binimetinib)
Phase 1/2
Novartis Pharmaceuticals
Recruiting
Last update posted :
09/14/2021
Initiation :
02/24/2021
Primary completion :
08/21/2024
Completion :
08/21/2024
KRAS
|
KRAS mutation
|
spartalizumab (PDR001) • JDQ443 • TNO-155
Phase N/A
Bayer
Recruiting
Last update posted :
09/14/2021
Initiation :
04/03/2020
Primary completion :
11/30/2027
Completion :
03/31/2028
NTRK1 • NTRK3 • NTRK2 • NTRK
|
NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • NTRK fusion
|
Vitrakvi (larotrectinib)
Phase 2
Seagen Inc.
Recruiting
Last update posted :
09/14/2021
Initiation :
09/30/2021
Primary completion :
10/31/2024
Completion :
10/31/2025
BRAF
|
BRAF mutation
|
Keytruda (pembrolizumab) • carboplatin • pemetrexed • SEA-CD40
Phase 3
GlaxoSmithKline
Recruiting
Last update posted :
09/14/2021
Initiation :
10/26/2020
Primary completion :
08/28/2024
Completion :
10/28/2024
PD-L1
|
Keytruda (pembrolizumab) • Zejula (niraparib)
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/13/2021
Initiation :
04/11/2018
Primary completion :
12/31/2026
Completion :
12/31/2026
ALB
|
PD-L1 expression
|
Keytruda (pembrolizumab) • decitabine
Phase N/A
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/13/2021
Initiation :
09/17/2020
Primary completion :
09/16/2025
Completion :
09/16/2025
MSI
|
MSI-H/dMMR
Phase 1
AbbVie
Recruiting
Last update posted :
09/13/2021
Initiation :
01/15/2014
Primary completion :
06/30/2022
Completion :
12/26/2024
EGFR • MET
|
EGFR mutation • EGFR L858R
|
Opdivo (nivolumab) • erlotinib • Tagrisso (osimertinib) • telisotuzumab vedotin (ABBV-399) • telisotuzumab (h224G11)
Phase 3
Boehringer Ingelheim
Active, not recruiting
Last update posted :
09/13/2021
Initiation :
07/17/2013
Primary completion :
04/30/2018
Completion :
12/31/2021
EGFR
|
EGFR mutation
|
Gilotrif (afatinib)
Phase 3
Novartis Pharmaceuticals
Active, not recruiting
Last update posted :
09/13/2021
Initiation :
12/21/2018
Primary completion :
08/09/2021
Completion :
09/22/2022
PD-L1
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • Abraxane (albumin-bound paclitaxel) • pemetrexed • Ilaris (canakinumab)
Phase 2
Institut Claudius Regaud
Recruiting
Last update posted :
09/13/2021
Initiation :
05/27/2021
Primary completion :
12/01/2025
Completion :
12/01/2025
EGFR • ALK • CTLA4
|
Imfinzi (durvalumab)
Phase 2
Novartis Pharmaceuticals
Recruiting
Last update posted :
09/13/2021
Initiation :
05/17/2021
Primary completion :
12/12/2023
Completion :
01/23/2024
EGFR • ALK • MET
|
EGFR mutation • ALK rearrangement • MET mutation
|
Tabrecta (capmatinib)
Phase 1
Betta Pharmaceuticals Co., Ltd.
Recruiting
Last update posted :
09/13/2021
Initiation :
03/01/2017
Primary completion :
11/01/2024
Completion :
11/01/2024
MET
|
MET exon 14 mutation • MET expression
|
BPI-9016M
Phase 1/2
Genprex, Inc.
Recruiting
Last update posted :
09/13/2021
Initiation :
09/03/2021
Primary completion :
09/01/2024
Completion :
08/01/2025
EGFR
|
EGFR mutation
|
Tagrisso (osimertinib) • Reqorsa (quaratusugene ozeplasmid)
Phase 2
Novartis Pharmaceuticals
Recruiting
Last update posted :
09/13/2021
Initiation :
11/05/2019
Primary completion :
11/10/2022
Completion :
03/21/2023
CD8 • IL6
|
Keytruda (pembrolizumab) • Ilaris (canakinumab)
Phase 1
Ascentage Pharma Group Inc.
Recruiting
Last update posted :
09/13/2021
Initiation :
05/27/2019
Primary completion :
05/01/2022
Completion :
05/01/2023
ALK • ROS1
|
ALK positive • ROS1 positive • ROS1 fusion • ALK-ROS1 fusion
|
APG-2449
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
09/13/2021
Initiation :
03/04/2013
Primary completion :
12/03/2019
Completion :
12/03/2019
HER-2 • ALK
|
HR positive • HER-2 expression
|
AdHER2/neu DC Vaccine
Phase 1
Novartis Pharmaceuticals
Completed
Last update posted :
09/13/2021
Initiation :
05/24/2017
Primary completion :
07/28/2021
Completion :
08/11/2021
EGFR • ALK • ROS1
|
ALK rearrangement • ALK negative
|
cisplatin • carboplatin • paclitaxel • gemcitabine • pemetrexed • spartalizumab (PDR001) • Ilaris (canakinumab)
Phase 1a/1b
Hoffmann-La Roche
Active, not recruiting
Last update posted :
09/13/2021
Initiation :
12/07/2015
Primary completion :
12/31/2021
Completion :
12/31/2021
CD20
|
EGFR positive
|
Herceptin (trastuzumab) • Erbitux (cetuximab) • simlukafusp alfa (RG7461)
Phase 2
Ambrx, Inc.
Not yet recruiting
Last update posted :
09/13/2021
Initiation :
10/01/2021
Primary completion :
11/01/2023
Completion :
12/01/2024
HER-2
|
HER-2 amplification
|
ARX788
Phase 1/2
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
09/13/2021
Initiation :
10/05/2017
Primary completion :
10/01/2023
Completion :
10/01/2023
NF2
|
NF2 mutation
|
cisplatin • pemetrexed • pevonedistat (MLN4924)
Phase 1b/2a
NeoImmuneTech
Recruiting
Last update posted :
09/13/2021
Initiation :
06/10/2020
Primary completion :
06/30/2022
Completion :
04/30/2023
BRAF • ALK • ROS1
|
EGFR mutation • BRAF mutation • ALK translocation • ROS1 mutation
|
Keytruda (pembrolizumab) • Hyleukin-7 (efineptakin alfa)
Phase 1b/2a
Noxopharm Limited
Not yet recruiting
Last update posted :
09/10/2021
Initiation :
09/24/2021
Primary completion :
10/31/2022
Completion :
02/28/2024
ER
|
Veyonda (idronoxil)
Phase 1
Janssen Research & Development, LLC
Recruiting
Last update posted :
09/10/2021
Initiation :
09/04/2019
Primary completion :
02/28/2022
Completion :
10/31/2024
EGFR • MET
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR expression • EGFR exon 20 insertion • EGFR exon 20 mutation • MET expression
|
Tagrisso (osimertinib) • carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
Phase 2
Gilead Sciences
Recruiting
Last update posted :
09/10/2021
Initiation :
09/01/2021
Primary completion :
03/01/2024
Completion :
03/01/2025
EGFR • ALK • ROS1 • NTRK
|
MET exon 14 mutation
|
docetaxel • magrolimab (Hu5F9-G4)
Phase 1
Carisma Therapeutics Inc
Recruiting
Last update posted :
09/10/2021
Initiation :
02/02/2021
Primary completion :
02/01/2022
Completion :
02/01/2023
HER-2
|
HER-2 positive • HER-2 overexpression
|
CT-0508
Phase 1/2
Janssen Research & Development, LLC
Active, not recruiting
Last update posted :
09/10/2021
Initiation :
10/16/2019
Primary completion :
01/08/2021
Completion :
08/01/2022
EGFR
|
EGFR mutation
|
Leclaza (lazertinib)
Phase 2
Zhejiang Cancer Hospital
Recruiting
Last update posted :
09/10/2021
Initiation :
01/01/2020
Primary completion :
06/30/2022
Completion :
06/30/2023
EGFR • ROS1
|
EGFR mutation • ALK rearrangement
|
AiRuiKa (camrelizumab)
Phase 3
AstraZeneca
Recruiting
Last update posted :
09/10/2021
Initiation :
11/30/2020
Primary completion :
11/28/2025
Completion :
10/29/2027
PD-L1
|
PD-L1 expression
|
Imfinzi (durvalumab)
Phase 1a/1b
Genentech, Inc.
Recruiting
Last update posted :
09/10/2021
Initiation :
12/21/2017
Primary completion :
02/01/2024
Completion :
02/01/2024
HER-2 • ER • PGR
|
HER-2 negative • PGR negative
|
Tecentriq (atezolizumab) • autogene cevumeran (RG6180)
Phase 1b/2
Sumitomo Dainippon Pharma Oncology, Inc
Recruiting
Last update posted :
09/10/2021
Initiation :
12/14/2017
Primary completion :
08/01/2023
Completion :
02/01/2024
MSI • HLA-A
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • adegramotide/nelatimotide (DSP-7888)
Phase 1/2
Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Active, not recruiting
Last update posted :
09/10/2021
Initiation :
01/01/2015
Primary completion :
12/01/2022
Completion :
03/01/2023
EGFR
|
EGFR mutation • EGFR T790M
|
abivertinib (AC0010MA)
Phase 1b
Janssen Research & Development, LLC
Recruiting
Last update posted :
09/10/2021
Initiation :
11/10/2020
Primary completion :
04/03/2023
Completion :
12/29/2024
EGFR • MET
|
Lispro-PH20 (insulin lispro/rHuPH20) • amivantamab SC (Ami-LC)
Phase 1a/1b
Boehringer Ingelheim
Recruiting
Last update posted :
09/10/2021
Initiation :
06/11/2019
Primary completion :
09/09/2022
Completion :
05/15/2024
BRAF • ALK • TP53 • MDM2
|
TP53 mutation • BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • ALK rearrangement
|
BI 907828 • ezabenlimab (BI 754091) • miptenalimab (BI 754111)
Phase 2
Pfizer
Recruiting
Last update posted :
09/10/2021
Initiation :
09/16/2020
Primary completion :
09/28/2025
Completion :
09/28/2026
HER-2
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
|
Ibrance (palbociclib) • fulvestrant • letrozole • PF-07104091
Phase 2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
09/09/2021
Initiation :
03/17/2017
Primary completion :
03/01/2022
Completion :
03/01/2023
EGFR • HER-2
|
EGFR mutation • EGFR exon 20 insertion • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 V777L • HER-2 exon 20 insertion • EGFR exon 20 mutation • HER-2 A775 • HER-2 P780-Y781insGSP
|
poziotinib (HM 78136B)
Phase 1b/2
Eli Lilly and Company
Completed
Last update posted :
09/09/2021
Initiation :
01/01/2015
Primary completion :
12/13/2018
Completion :
07/08/2020
EGFR • ALK • AFP
|
EGFR mutation • ALK positive • ALK fusion • AFP elevation
|
Opdivo (nivolumab) • cisplatin • galunisertib (LY2157299)
Phase N/A
University of Calgary
Recruiting
Last update posted :
09/09/2021
Initiation :
11/01/2019
Primary completion :
07/30/2022
Completion :
10/30/2022
EGFR • ALK
|
EGFR mutation
Phase 2
Hoffmann-La Roche
Recruiting
Last update posted :
09/09/2021
Initiation :
12/14/2020
Primary completion :
05/06/2023
Completion :
11/14/2025
PD-L1
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • Tecentriq (atezolizumab) • pemetrexed • tiragolumab (MTIG7192A)
Phase 2
European Thoracic Oncology Platform
Recruiting
Last update posted :
09/09/2021
Initiation :
07/01/2020
Primary completion :
12/30/2022
Completion :
03/30/2023
EGFR
|
EGFR mutation • EGFR L858R • EGFR T790M • EGFR G719X • EGFR S768I
|
Avastin (bevacizumab) • carboplatin • Tecentriq (atezolizumab) • paclitaxel • pemetrexed
Phase 1/2
BeiGene
Recruiting
Last update posted :
09/09/2021
Initiation :
11/13/2018
Primary completion :
07/01/2023
Completion :
01/01/2024
PD-L1
|
PD-L1 expression
|
Baize’an (tislelizumab) • BGB-A425
Phase 3
Daiichi Sankyo, Inc.
Recruiting
Last update posted :
09/09/2021
Initiation :
12/21/2020
Primary completion :
10/27/2022
Completion :
06/27/2024
EGFR • BRAF • PD-L1 • ALK • NTRK
|
docetaxel • datopotamab deruxtecan (DS-1062a)
Phase 1
Astellas Pharma Inc
Active, not recruiting
Last update posted :
09/09/2021
Initiation :
10/30/2019
Primary completion :
12/31/2021
Completion :
12/31/2021
EGFR • ALK
|
EGFR mutation • ALK positive • ALK mutation
|
ASP1948
Phase 2
Eli Lilly and Company
Active, not recruiting
Last update posted :
09/09/2021
Initiation :
08/28/2013
Primary completion :
03/14/2016
Completion :
12/31/2022
EGFR
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X
|
erlotinib • emibetuzumab (LY2875358)
Phase 1/2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
09/09/2021
Initiation :
01/21/2016
Primary completion :
09/03/2021
Completion :
09/07/2022
EGFR
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR exon 20 mutation
|
erlotinib • onalespib (AT13387)
Phase 1
The Methodist Hospital Research Institute
Recruiting
Last update posted :
09/09/2021
Initiation :
08/03/2018
Primary completion :
10/31/2021
Completion :
01/28/2022
BRAF • PD-L1 • TMB • MSI
|
PD-L1 expression • TMB-H • MSI-H/dMMR • BRAF mutation
|
Keytruda (pembrolizumab)
Phase 1
Sanofi
Recruiting
Last update posted :
09/09/2021
Initiation :
08/23/2021
Primary completion :
06/16/2025
Completion :
06/16/2025
HER-2
|
HER-2 expression
|
SAR443216
Phase N/A
Oncodesign SA
Recruiting
Last update posted :
09/09/2021
Initiation :
01/06/2018
Primary completion :
12/31/2021
Completion :
03/31/2023
HER-2 • PGR
|
HER-2 negative
Phase 1/2
Jacobio Pharmaceuticals Co., Ltd.
Recruiting
Last update posted :
09/09/2021
Initiation :
09/03/2021
Primary completion :
07/01/2023
Completion :
07/01/2025
KRAS
|
KRAS mutation • KRAS G12C • KRAS G12
|
Erbitux (cetuximab) • JAB-21822
Phase 2
BeiGene
Not yet recruiting
Last update posted :
09/09/2021
Initiation :
09/01/2021
Primary completion :
12/01/2023
Completion :
12/01/2024
PD-L1
|
lenvatinib • Baize’an (tislelizumab)
Phase 1
Molecular Templates, Inc.
Recruiting
Last update posted :
09/09/2021
Initiation :
05/27/2021
Primary completion :
04/01/2025
Completion :
05/01/2026
PD-L1
|
PD-L1 expression
|
MT-6402
Phase 1
Novartis Pharmaceuticals
Recruiting
Last update posted :
09/08/2021
Initiation :
02/24/2017
Primary completion :
01/11/2022
Completion :
05/19/2022
BRAF • KRAS • NRAS • DUSP6
|
KRAS mutation • BRAF mutation • NRAS mutation
|
Mekinist (trametinib) • Kisqali (ribociclib) • naporafenib (LXH254) • rineterkib (LTT462)
Phase 1
Boehringer Ingelheim
Active, not recruiting
Last update posted :
09/08/2021
Initiation :
06/13/2017
Primary completion :
12/26/2022
Completion :
12/26/2022
EGFR • ALK • TMB • MSI
|
PD-L1 expression • TMB-H • MSI-H/dMMR • PD-L1 overexpression
|
ezabenlimab (BI 754091) • miptenalimab (BI 754111)
Phase 1
Boehringer Ingelheim
Not yet recruiting
Last update posted :
09/08/2021
Initiation :
09/22/2021
Primary completion :
03/15/2024
Completion :
01/02/2025
FAP
|
BI 765179 • ezabenlimab (BI 754091)
Phase 2
Bayer
Recruiting
Last update posted :
09/08/2021
Initiation :
09/30/2015
Primary completion :
08/15/2023
Completion :
09/30/2025
NTRK1 • NTRK3 • NTRK2 • NTRK
|
NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • NTRK fusion
|
Vitrakvi (larotrectinib)
Phase N/A
Novartis Pharmaceuticals
Available
Last update posted :
09/08/2021
MET
|
MET exon 14 mutation
|
Tabrecta (capmatinib)
Phase 1
The Methodist Hospital Research Institute
Not yet recruiting
Last update posted :
09/08/2021
Initiation :
09/01/2021
Primary completion :
06/01/2023
Completion :
06/01/2024
PD-L1 • CD4
|
PD-L1 expression
|
Tecentriq (atezolizumab) • ADV/IL-12 gene therapy
Phase 2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
09/08/2021
Initiation :
06/30/2021
Primary completion :
03/31/2023
Completion :
03/31/2023
EGFR • CD4
|
EGFR mutation • EGFR L858R • EGFR T790M • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR G719X • EGFR exon 20 mutation • EGFR exon 18 mutation
|
cisplatin • carboplatin • pemetrexed • bintrafusp alfa (M7824)
Phase 2
Chloe Atreya, MD, PhD
Recruiting
Last update posted :
09/08/2021
Initiation :
07/12/2019
Primary completion :
06/30/2023
Completion :
06/30/2023
PD-L1 • MLH1 • MSH6 • MSH2
|
Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • vactosertib (TEW-7197)
Phase N/A
Boehringer Ingelheim
Recruiting
Last update posted :
09/08/2021
Initiation :
05/20/2020
Primary completion :
08/30/2026
Completion :
08/30/2026
EGFR
|
EGFR mutation
|
Gilotrif (afatinib)
Phase N/A
Centre Hospitalier Intercommunal Creteil
Recruiting
Last update posted :
09/08/2021
Initiation :
03/17/2021
Primary completion :
09/01/2021
Completion :
09/01/2021
ROS1
|
Alunbrig (brigatinib)
Phase 2
AIO-Studien-gGmbH
Active, not recruiting
Last update posted :
09/08/2021
Initiation :
06/18/2018
Primary completion :
10/01/2021
Completion :
10/01/2023
ALB
|
Keytruda (pembrolizumab)
Phase 2
Sarah Goldberg
Not yet recruiting
Last update posted :
09/08/2021
Initiation :
10/01/2021
Primary completion :
10/01/2025
Completion :
10/01/2025
PD-L1
|
Keytruda (pembrolizumab) • sitravatinib (MGCD516)
Phase 2
AstraZeneca
Recruiting
Last update posted :
09/08/2021
Initiation :
06/25/2019
Primary completion :
05/27/2025
Completion :
05/27/2025
EGFR
|
EGFR mutation
|
Tagrisso (osimertinib) • gefitinib • carboplatin • Imfinzi (durvalumab) • Alecensa (alectinib) • pemetrexed • Retevmo (selpercatinib) • Orpathys (savolitinib) • Portrazza (necitumumab)
Phase 1
Dwight Owen
Not yet recruiting
Last update posted :
09/08/2021
Initiation :
10/01/2021
Primary completion :
12/31/2023
Completion :
12/31/2024
PD-L1 • ALK
|
Tecentriq (atezolizumab) • Vesanoid (tretinoin)
Phase 1b
Nouscom SRL
Recruiting
Last update posted :
09/08/2021
Initiation :
04/07/2021
Primary completion :
10/31/2024
Completion :
10/31/2024
EGFR • PD-L1 • ALK • ROS1
|
PD-L1 expression
|
Keytruda (pembrolizumab) • NOUS-PEV
Phase 1
AbbVie
Recruiting
Last update posted :
09/08/2021
Initiation :
07/13/2018
Primary completion :
09/29/2022
Completion :
09/29/2022
HER-2 • CD276
|
HER-2 positive • HR positive • HER-2 negative • CD276 expression • HR positive + HER-2 negative
|
paclitaxel • docetaxel • mirzotamab clezutoclax (ABBV-155)
Phase 2
National University Hospital, Singapore
Recruiting
Last update posted :
09/08/2021
Initiation :
06/21/2021
Primary completion :
06/01/2024
Completion :
06/01/2025
EGFR
|
EGFR mutation • EGFR T790M
|
Tagrisso (osimertinib)
Phase 1
Boehringer Ingelheim
Recruiting
Last update posted :
09/08/2021
Initiation :
07/15/2020
Primary completion :
04/01/2024
Completion :
04/01/2024
DLL3
|
DLL3 expression
|
BI 764532
Phase 
VastBiome
Not yet recruiting
Last update posted :
09/08/2021
Initiation :
09/14/2021
Primary completion :
09/14/2023
Completion :
09/14/2028
IFNG • TNFA • IL2 • IL10
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/08/2021
Initiation :
02/01/2021
Primary completion :
12/31/2022
Completion :
12/31/2022
HER-2 • ER • PGR • ATM
|
HER-2 negative • ATM mutation • ATM expression
|
cisplatin • gemcitabine • elimusertib (BAY1895344) • liposomal gemcitabine (FF-10832)
Phase 1
Boehringer Ingelheim
Recruiting
Last update posted :
09/08/2021
Initiation :
06/22/2021
Primary completion :
09/25/2023
Completion :
10/24/2023
HER-2 • BRAF • ALK • NRG1
|
BRAF V600E • EGFR mutation • HER-2 amplification • HER-2 overexpression • BRAF V600 • EGFR T790M • HER-2 mutation • ALK rearrangement • HER-2 exon 20 insertion • HER-2 exon 20 mutation
|
BI 1810631
Phase 1
Boehringer Ingelheim
Active, not recruiting
Last update posted :
09/08/2021
Initiation :
02/23/2018
Primary completion :
10/05/2021
Completion :
11/09/2021
EGFR • ALK
|
PD-L1 expression • ALK rearrangement
|
ezabenlimab (BI 754091) • miptenalimab (BI 754111)
Phase 1
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
09/08/2021
Initiation :
09/30/2015
Primary completion :
02/27/2020
ERCC1 • NKX2-1
|
cisplatin • pemetrexed • methoxyamine (TRC102)
Phase 2
National Cancer Institute (NCI)
Not yet recruiting
Last update posted :
09/06/2021
Initiation :
09/10/2021
Primary completion :
07/01/2024
Completion :
07/01/2024
SSTR • CD4
|
cisplatin • everolimus • Lutathera (lutetium Lu 177 dotatate)
Phase 1
Bayer
Recruiting
Last update posted :
09/06/2021
Initiation :
08/15/2019
Primary completion :
04/04/2023
Completion :
06/29/2023
IL6
|
BAY2416964
Phase N/A
University Hospital, Tours
Recruiting
Last update posted :
09/06/2021
Initiation :
09/03/2021
Primary completion :
09/01/2022
Completion :
09/01/2022
PD-L1 • CD4
Phase N/A
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/06/2021
Initiation :
03/30/2021
Primary completion :
06/30/2038
Completion :
06/30/2038
BAP1
|
BAP1 mutation
Phase 2
Qianfoshan Hospital
Not yet recruiting
Last update posted :
09/06/2021
Initiation :
01/01/2022
Primary completion :
03/31/2023
Completion :
03/31/2025
EGFR
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion
|
Ameile (almonertinib)
Phase 2a
AstraZeneca
Recruiting
Last update posted :
09/06/2021
Initiation :
12/01/2020
Primary completion :
06/08/2023
Completion :
06/08/2023
ATM
|
ATM mutation
|
ceralasertib (AZD6738)
Phase N/A
Bristol-Myers Squibb
Recruiting
Last update posted :
09/06/2021
Initiation :
09/28/2020
Primary completion :
09/15/2025
Completion :
09/15/2025
EGFR • HER-2 • BRAF • PD-L1 • KRAS • ALK • MET • ROS1
|
PD-L1 expression • KRAS mutation • EGFR mutation • BRAF mutation • MET mutation • ALK translocation • ROS1 mutation
|
Opdivo (nivolumab)
Phase 1
GlaxoSmithKline
Completed
Last update posted :
09/06/2021
Initiation :
02/01/2016
Primary completion :
08/10/2020
Completion :
08/10/2020
EGFR • ALK • ROS1 • HLA-A • CTAG2
|
EGFR mutation • ALK rearrangement • CTAG2 expression
|
fludarabine IV • letetresgene autoleucel (GSK3377794) • cyclophosphamide intravenous
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
09/03/2021
Initiation :
02/08/2011
Primary completion :
12/31/2022
Completion :
12/31/2022
EGFR • BRAF
|
EGFR mutation
|
erlotinib • Sutent (sunitinib) • Koselugo (selumetinib) • lapatinib • MK-2206
Phase 1b
Merck Sharp & Dohme Corp.
Recruiting
Last update posted :
09/03/2021
Initiation :
06/19/2019
Primary completion :
06/07/2024
Completion :
06/07/2024
EGFR • ALK • ROS1 • MGMT
|
Keytruda (pembrolizumab) • carboplatin • gemcitabine • Abraxane (albumin-bound paclitaxel) • pemetrexed • MK-0482
Phase 1
Roswell Park Cancer Institute
Not yet recruiting
Last update posted :
09/03/2021
Initiation :
09/15/2021
Primary completion :
12/15/2022
Completion :
12/15/2023
PD-L1
|
PD-L1 expression
|
Photofrin (porfimer sodium)
Phase 1
Eli Lilly and Company
Active, not recruiting
Last update posted :
09/03/2021
Initiation :
09/29/2016
Primary completion :
02/10/2021
Completion :
09/10/2022
BRAF • NRAS
|
BRAF V600E • NRAS mutation • BRAF V600
|
Erbitux (cetuximab) • gemcitabine • Braftovi (encorafenib) • Verzenio (abemaciclib) • Abraxane (albumin-bound paclitaxel) • temuterkib (LY3214996) • midazolam hydrochloride
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/03/2021
Initiation :
09/11/2019
Primary completion :
04/30/2023
Completion :
03/31/2024
EGFR • PD-L1 • KRAS • ALK • ROS1 • MSLN
|
KRAS mutation • EGFR mutation • ALK rearrangement • MSLN expression
|
Keytruda (pembrolizumab) • LMB-100
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/03/2021
Initiation :
07/07/2021
Primary completion :
12/31/2025
Completion :
12/31/2026
BRCA
|
EGFR mutation
|
Lynparza (olaparib) • Imfinzi (durvalumab)
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/03/2021
Initiation :
08/24/2020
Primary completion :
04/02/2024
Completion :
04/08/2024
NF1
|
paclitaxel • Tasigna (nilotinib)
Phase 1/2
Shanghai EpimAb Biotherapeutics Co., Ltd.
Recruiting
Last update posted :
09/03/2021
Initiation :
12/13/2018
Primary completion :
03/14/2023
Completion :
03/14/2023
EGFR
|
EGFR mutation • EGFR T790M
|
EMB-01
Phase 2
Yale University
Recruiting
Last update posted :
09/03/2021
Initiation :
05/01/2016
Primary completion :
05/01/2023
Completion :
05/01/2024
PD-L1
|
PD-L1 expression
|
Keytruda (pembrolizumab) • Avastin (bevacizumab)
Phase 2
Spectrum Pharmaceuticals, Inc
Recruiting
Last update posted :
09/03/2021
Initiation :
10/13/2017
Primary completion :
03/01/2023
Completion :
12/30/2023
EGFR • HER-2
|
EGFR mutation • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR exon 20 mutation
|
Tagrisso (osimertinib) • poziotinib (HM 78136B)
Phase 3
AstraZeneca
Recruiting
Last update posted :
09/03/2021
Initiation :
12/16/2020
Primary completion :
03/26/2024
Completion :
03/29/2029
EGFR
|
EGFR mutation • EGFR L858R • EGFR T790M • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X
|
cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed
Phase N/A
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/03/2021
Initiation :
03/13/2019
Primary completion :
07/06/2026
Completion :
07/05/2027
TP53 • BAP1
|
TP53 mutation • BAP1 mutation
Phase 2
Yonsei University
Not yet recruiting
Last update posted :
09/03/2021
Initiation :
12/01/2021
Primary completion :
12/01/2023
Completion :
12/01/2023
PD-L1
|
PD-L1 expression
|
Tecentriq (atezolizumab) • tiragolumab (MTIG7192A)
Phase 1b
Astellas Pharma Global Development, Inc.
Recruiting
Last update posted :
09/03/2021
Initiation :
01/14/2019
Primary completion :
04/30/2024
Completion :
04/30/2024
EGFR • PD-L1 • ALK
|
PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK positive • ALK mutation
|
Keytruda (pembrolizumab) • ASP1951
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
09/03/2021
Initiation :
04/13/2016
Primary completion :
02/01/2022
Completion :
09/01/2022
EGFR
|
EGFR mutation • EGFR T790M
|
Tagrisso (osimertinib)
Phase 1b/2
Bayer
Active, not recruiting
Last update posted :
09/03/2021
Initiation :
10/17/2018
Primary completion :
03/31/2022
Completion :
03/31/2022
EGFR • PD-L1 • ALK
|
PD-L1 expression • EGFR expression
|
Opdivo (nivolumab) • Aliqopa (copanlisib)
Phase 1
Calithera Biosciences, Inc
Recruiting
Last update posted :
09/02/2021
Initiation :
01/19/2021
Primary completion :
05/01/2022
Completion :
07/01/2022
KEAP1 • NFE2L2
|
KEAP1 mutation • NFE2L2 mutation
Phase N/A
Novartis Pharmaceuticals
Recruiting
Last update posted :
09/02/2021
Initiation :
11/02/2020
Primary completion :
09/29/2023
Completion :
09/29/2023
MET
|
MET exon 14 mutation
|
Tabrecta (capmatinib)
Phase 2
Calithera Biosciences, Inc
Recruiting
Last update posted :
09/02/2021
Initiation :
07/24/2020
Primary completion :
07/01/2022
Completion :
10/01/2024
BRAF • ALK • ROS1 • STK11 • KEAP1 • NTRK
|
BRAF mutation • STK11 mutation • KEAP1 mutation • NFE2L2 mutation
|
Keytruda (pembrolizumab) • carboplatin • pemetrexed • dexamethasone • telaglenastat (CB-839)
Phase 1/2
Amgen
Recruiting
Last update posted :
09/02/2021
Initiation :
08/27/2018
Primary completion :
01/27/2026
Completion :
01/27/2026
KRAS
|
KRAS mutation • KRAS G12C • KRAS G12
|
Lumakras (sotorasib) • midazolam hydrochloride
Phase 2
Novartis Pharmaceuticals
Active, not recruiting
Last update posted :
09/02/2021
Initiation :
06/11/2015
Primary completion :
02/07/2023
Completion :
03/23/2023
EGFR • ALK
|
ALK rearrangement • ALK negative
|
Tabrecta (capmatinib)
Phase 2
Nasser Hanna
Recruiting
Last update posted :
09/02/2021
Initiation :
05/22/2020
Primary completion :
01/01/2023
Completion :
01/01/2024
PD-L1
|
cisplatin • Tecentriq (atezolizumab) • docetaxel • pemetrexed
Phase 2
Soroka University Medical Center
Active, not recruiting
Last update posted :
09/02/2021
Initiation :
05/01/2016
Primary completion :
12/31/2022
Completion :
12/31/2022
EGFR
|
EGFR mutation • EGFR L858R • EGFR T790M • EGFR exon 19 deletion
|
Tagrisso (osimertinib)
Phase 3
Hutchison Medipharma Limited
Recruiting
Last update posted :
09/02/2021
Initiation :
08/19/2021
Primary completion :
07/01/2024
Completion :
12/01/2024
MET
|
MET exon 14 mutation • MET mutation
|
Orpathys (savolitinib)
Phase 3
Novartis Pharmaceuticals
Active, not recruiting
Last update posted :
09/02/2021
Initiation :
07/09/2013
Primary completion :
06/24/2016
Completion :
12/14/2023
ALK
|
ALK positive
|
cisplatin • carboplatin • Zykadia (ceritinib) • pemetrexed
Phase 3
AstraZeneca
Active, not recruiting
Last update posted :
09/02/2021
Initiation :
01/13/2015
Primary completion :
02/09/2018
Completion :
12/31/2021
PD-L1
|
erlotinib • Imfinzi (durvalumab) • gemcitabine • tremelimumab (CP-675206) • vinorelbine tartrate
Phase 2
EMD Serono Research & Development Institute, Inc.
Recruiting
Last update posted :
09/02/2021
Initiation :
09/19/2019
Primary completion :
11/30/2022
Completion :
03/30/2023
EGFR • MET
|
EGFR mutation • MET amplification
|
Tagrisso (osimertinib) • Tepmetko (tepotinib)
Phase 2
Anita Turk
Recruiting
Last update posted :
09/02/2021
Initiation :
09/28/2020
Primary completion :
06/01/2022
Completion :
09/01/2022
BRAF • MAP2K1 • NF1
|
BRAF V600E • BRAF V600 • NF1 mutation • MAP2K1 mutation • RAF1 amplification
|
Verzenio (abemaciclib) • temuterkib (LY3214996)
Phase N/A
xCures
Available
Last update posted :
09/02/2021
BRAF • NRAS • HRAS
|
BRAF mutation • ER mutation • HRAS mutation
|
ulixertinib (BVD-523)
Phase 2
National Cancer Institute (NCI)
Not yet recruiting
Last update posted :
09/02/2021
Initiation :
11/01/2021
Primary completion :
10/31/2024
Completion :
10/31/2024
PD-1
|
PD-1 expression
|
metformin hydrochloride extended release
Phase 1/2
Bavarian Nordic
Recruiting
Last update posted :
09/02/2021
Initiation :
08/10/2020
Primary completion :
12/01/2022
Completion :
12/01/2024
ER • PGR
|
HER-2 positive • HER-2 amplification • HER-2 negative • HER-2 expression • ER positive + PGR positive • PGR positive
|
TAEK-VAC-HerBy vaccine
Phase 1/2
Ipsen
Active, not recruiting
Last update posted :
09/01/2021
Initiation :
03/06/2017
Primary completion :
05/01/2022
Completion :
05/01/2022
SSTR
|
SSTR positive
|
dexamethasone • SOMther (lutetium-177 DOTA satoreotide) • ondansetron
Phase 2
Georgetown University
Not yet recruiting
Last update posted :
09/01/2021
Initiation :
10/01/2021
Primary completion :
07/01/2023
Completion :
07/01/2024
ALK • ROS1
|
PD-L1 expression
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • tiragolumab (MTIG7192A)
Phase 1b/2
Amgen
Recruiting
Last update posted :
09/01/2021
Initiation :
12/17/2019
Primary completion :
01/12/2024
Completion :
11/30/2025
KRAS
|
KRAS mutation • KRAS G12C • KRAS G12
|
Keytruda (pembrolizumab) • Avastin (bevacizumab) • Mekinist (trametinib) • Gilotrif (afatinib) • carboplatin • Tecentriq (atezolizumab) • Ibrance (palbociclib) • 5-fluorouracil • everolimus • docetaxel • Vectibix (panitumumab) • oxaliplatin • irinotecan • Lumakras (sotorasib) • pemetrexed • leucovorin calcium • SAR442720 • TNO-155 • zeluvalimab (AMG 404)
Phase N/A
Pfizer
Recruiting
Last update posted :
09/01/2021
Initiation :
10/25/2017
Primary completion :
02/06/2026
Completion :
02/06/2026
ROS1
|
ROS1 positive
|
Xalkori (crizotinib)
Phase 2
Sidney Kimmel Cancer Center at Thomas Jefferson...
Active, not recruiting
Last update posted :
09/01/2021
Initiation :
12/20/2017
Primary completion :
07/01/2022
Completion :
07/01/2022
PD-L1
|
Opdivo (nivolumab) • cisplatin • gemcitabine • pemetrexed
Phase 2
AstraZeneca
Recruiting
Last update posted :
09/01/2021
Initiation :
01/09/2019
Primary completion :
12/02/2021
Completion :
02/15/2023
EGFR • MET
|
EGFR mutation • EGFR L858R • MET amplification • EGFR exon 19 deletion • EGFR amplification • MET overexpression
|
Tagrisso (osimertinib) • Orpathys (savolitinib)
Phase 1b
Astellas Pharma Global Development, Inc.
Recruiting
Last update posted :
09/01/2021
Initiation :
07/02/2018
Primary completion :
04/30/2024
Completion :
04/30/2024
EGFR • PD-L1 • ALK
|
PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK positive • ALK mutation
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • ASP1948
Phase 1/2
Klus Pharma Inc.
Recruiting
Last update posted :
09/01/2021
Initiation :
02/28/2020
Primary completion :
12/01/2021
Completion :
12/01/2022
TROP2
|
TROP2 expression
|
SKB264
Phase 1
Mirati Therapeutics Inc.
Recruiting
Last update posted :
09/01/2021
Initiation :
08/12/2021
Primary completion :
11/30/2023
Completion :
02/28/2024
KRAS
|
KRAS mutation • KRAS G12C • KRAS G12
|
adagrasib (MRTX849) • BI 1701963
Phase 2
Lytix Biopharma AS
Recruiting
Last update posted :
09/01/2021
Initiation :
06/01/2021
Primary completion :
12/31/2022
Completion :
08/31/2023
BRAF • MSI • BRCA
|
PD-L1 expression • MSI-H/dMMR • BRAF mutation • BRCA mutation
|
Keytruda (pembrolizumab) • cisplatin • Oncopore (ruxotemitide)
Phase 1/2
Klus Pharma Inc.
Recruiting
Last update posted :
09/01/2021
Initiation :
07/16/2018
Primary completion :
04/01/2022
Completion :
12/01/2022
HER-2
|
HER-2 positive • HER-2 expression • HER-2 underexpression
|
A166
Phase 1/2
Blueprint Medicines Corporation
Recruiting
Last update posted :
09/01/2021
Initiation :
06/29/2021
Primary completion :
01/31/2025
Completion :
01/31/2025
EGFR
|
EGFR mutation • EGFR T790M • EGFR C797S • EGFR T790M + C797S
|
BLU-945
Phase 2
Joel Neal
Active, not recruiting
Last update posted :
09/01/2021
Initiation :
10/01/2016
Primary completion :
03/19/2021
Completion :
04/07/2022
PD-L1 • ALK
|
PD-L1 expression • EGFR mutation • ALK rearrangement
|
Keytruda (pembrolizumab)
Phase 1
AbbVie
Not yet recruiting
Last update posted :
09/01/2021
Initiation :
09/01/2021
Primary completion :
06/28/2025
Completion :
06/28/2025
MET
|
MET positive
|
ABBV-400
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/01/2021
Initiation :
11/09/2020
Primary completion :
09/30/2022
Completion :
09/30/2022
BRAF • KRAS • ALK • ROS1 • KEAP1 • NFE2L2
|
BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • BRAF V600K • KEAP1 mutation • NFE2L2 mutation
|
sapanisertib (TAK-228) • telaglenastat (CB-839)
Phase 3
Rennes University Hospital
Active, not recruiting
Last update posted :
09/01/2021
Initiation :
02/19/2018
Primary completion :
07/31/2021
Completion :
07/01/2022
PD-L1
|
Opdivo (nivolumab) • carboplatin • Yervoy (ipilimumab) • paclitaxel
Phase 2
Flame Biosciences
Recruiting
Last update posted :
09/01/2021
Initiation :
08/25/2021
Primary completion :
10/30/2022
Completion :
02/01/2023
CRP
|
Opdivo (nivolumab) • FL-101
Phase 1
Keythera Pharmaceuticals (Australia) Pty Ltd
Recruiting
Last update posted :
09/01/2021
Initiation :
03/09/2021
Primary completion :
12/31/2022
Completion :
12/31/2022
PD-L1 • CD8 • IFNG • CXCL10 • TNFA
|
PD-L1 expression
|
Tecentriq (atezolizumab) • KF-0210
Phase 2
Institut Bergonié
Recruiting
Last update posted :
09/01/2021
Initiation :
08/27/2021
Primary completion :
08/01/2023
Completion :
08/01/2024
PD-L1
Phase 1b/2
Revolution Medicines, Inc.
Active, not recruiting
Last update posted :
09/01/2021
Initiation :
07/02/2019
Primary completion :
03/31/2022
Completion :
04/30/2022
EGFR • BRAF • KRAS • NF1
|
KRAS mutation • EGFR mutation • BRAF mutation • NF1 mutation • BRAF amplification
|
Tagrisso (osimertinib) • Cotellic (cobimetinib) • SAR442720
Phase 1
Revolution Medicines, Inc.
Recruiting
Last update posted :
08/31/2021
Initiation :
09/28/2018
Primary completion :
10/01/2021
Completion :
10/01/2021
BRAF • KRAS • NF1
|
BRAF mutation • KRAS G12C • KRAS G12 • KRAS amplification • BRAF amplification
|
SAR442720
Phase 1/2
Ascentage Pharma Group Inc.
Recruiting
Last update posted :
08/31/2021
Initiation :
08/29/2018
Primary completion :
10/30/2022
Completion :
01/31/2023
PD-L1 • ATM
|
ATM mutation
|
Keytruda (pembrolizumab) • alrizomadlin (APG-115)
Phase N/A
Massachusetts General Hospital
Not yet recruiting
Last update posted :
08/31/2021
Initiation :
09/01/2021
Primary completion :
06/01/2025
Completion :
06/01/2025
ALK • TMB
|
PD-L1 expression • ALK rearrangement • ALK mutation
Phase 1/2
Fred Hutchinson Cancer Research Center
Recruiting
Last update posted :
08/31/2021
Initiation :
07/19/2021
Primary completion :
12/01/2024
Completion :
12/01/2024
HER-2 • ALK • ROS1 • HLA-A • MAGEA1
|
EGFR mutation • HER-2 expression
|
Tecentriq (atezolizumab) • fludarabine IV • cyclophosphamide intravenous
Phase 2
Ruijin Hospital
Not yet recruiting
Last update posted :
08/31/2021
Initiation :
10/01/2021
Primary completion :
08/01/2022
Completion :
08/01/2022
EGFR
|
EGFR L858R • EGFR T790M • EGFR exon 19 deletion
|
furmonertinib (AST2818)
Phase 1/2
Hutchison Medipharma Limited
Recruiting
Last update posted :
08/31/2021
Initiation :
03/05/2021
Primary completion :
02/27/2023
Completion :
04/30/2023
PD-L1
|
Baize’an (tislelizumab) • Sulanda (surufatinib)
Phase 1
Hutchison Medipharma Limited
Recruiting
Last update posted :
08/31/2021
Initiation :
11/10/2017
Primary completion :
12/15/2021
Completion :
06/30/2022
HER-2
|
HR positive • HER-2 negative
|
Elunate (fruquintinib)
Phase N/A
Henan Cancer Hospital
Recruiting
Last update posted :
08/31/2021
Initiation :
03/20/2021
Primary completion :
02/20/2023
Completion :
02/20/2024
EGFR
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion
|
Ameile (almonertinib)
Phase 2
Dana-Farber Cancer Institute
Active, not recruiting
Last update posted :
08/31/2021
Initiation :
11/11/2016
Primary completion :
10/01/2020
Completion :
03/01/2024
EGFR • ALK • MET • NTRK1 • NTRK
|
MET exon 14 mutation
|
merestinib (LY2801653)
Phase 2
Hutchison Medipharma Limited
Active, not recruiting
Last update posted :
08/31/2021
Initiation :
12/01/2016
Primary completion :
09/30/2021
Completion :
12/30/2021
MET
|
MET exon 14 mutation • MET mutation
|
Orpathys (savolitinib)
Phase 2
Kartos Therapeutics, Inc.
Not yet recruiting
Last update posted :
08/30/2021
Initiation :
11/01/2021
Primary completion :
05/01/2025
Completion :
11/01/2025
PD-L1
|
navtemadlin (KRT-232)
Phase N/A
Rutgers, The State University of New Jersey
Recruiting
Last update posted :
08/30/2021
Initiation :
09/01/2017
Primary completion :
08/31/2021
Completion :
08/31/2021
NFKB1
Phase 1
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
08/30/2021
Initiation :
11/21/2018
Primary completion :
11/01/2023
Completion :
11/01/2023
EGFR
|
EGFR mutation
|
Tagrisso (osimertinib) • Vizimpro (dacomitinib)